Core Viewpoint - Guichuang Tongqiao (02190) has issued a positive profit forecast for the year 2025, expecting a significant increase in net profit and revenue compared to the previous year [1][2]. Group 1: Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year growth of approximately 139.4% [1]. - Revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year increase of about 34.6% [1]. Group 2: Product Performance - Sales of core products such as the Tongqiao Qilin™ blood flow guiding device, neurovascular guidewires, UltraFree drug-eluting PTA balloon dilatation catheters, and ZYLOX Swan venous intraluminal radiofrequency closure catheters have all seen rapid growth [1]. Group 3: International Expansion - The company has achieved a key breakthrough in its internationalization strategy, with sales channels covering 83 countries and regions globally and over 80 strategic partnerships established with overseas partners [2]. - A strategic acquisition of the German company Optimed was announced in January 2026, aimed at further expanding the company's presence in Europe and globally, while enhancing global operational and delivery capabilities through synergies between production bases in China and Germany [2].
港股异动 | 归创通桥(02190)盈喜后涨超5% 预期25年度净利同比增近1.4倍 国际化战略实现关键突破